{"id":117215,"date":"2026-03-05T04:06:43","date_gmt":"2026-03-05T04:06:43","guid":{"rendered":"https:\/\/mailinvest.blog\/index.php\/2026\/03\/05\/what-to-know-about-how-glp-1-medications-might-fight-addiction\/"},"modified":"2026-03-05T04:06:57","modified_gmt":"2026-03-05T04:06:57","slug":"what-to-know-about-how-glp-1-medications-might-fight-addiction","status":"publish","type":"post","link":"https:\/\/mailinvest.blog\/index.php\/2026\/03\/05\/what-to-know-about-how-glp-1-medications-might-fight-addiction\/","title":{"rendered":"What to know about how GLP-1 medications might fight addiction"},"content":{"rendered":"

<\/a>\n
<\/p>\n

\n

The blockbuster GLP-1 medication which have reshaped the treatment<\/a> of diabetes and weight problems might assist forestall a number of substance use problems \u2014 and scale back the tragic outcomes they trigger, a big new examine finds. <\/p>\n

An evaluation published Wednesday<\/a> in a medical journal checked out digital well being information from greater than 600,000 U.S. Veterans Affairs sufferers with diabetes. It discovered that these handled with medicines akin to Ozempic and Mounjaro had been much less prone to develop addictions to alcohol,<\/a> nicotine, cocaine, opioids and different substances than these handled with a distinct class of medication.<\/p>\n

In these already addicted, the GLP-1 medication had been linked to decrease dangers of hospitalization, overdose and loss of life, in accordance with the examine.<\/p>\n

The brand new outcomes recommend \u2014 however don\u2019t show \u2014 that the weight-loss medicines could possibly goal the underlying supply of cravings that have an effect on the greater than 48 million Individuals with substance use problems. <\/p>\n

\u201cThey’re truly working towards the foundation reason behind all these completely different addictions,\u201d stated Dr. Ziyad Al-Aly, the examine\u2019s lead writer and a chief researcher on the VA St. Louis Well being Care System. <\/p>\n

Right here\u2019s what you’ll want to know concerning the new analysis revealed by The BMJ:<\/p>\n

Earlier research have steered that the medication generally known as GLP-1s, or glucagon-like peptide-1 receptor agonists, might scale back addictions by concentrating on the mind’s reward pathways. However these research have been small and infrequently restricted to 1 substance. <\/p>\n

For this examine, one of many largest up to now, Al-Aly and his colleagues analyzed knowledge from the digital information of greater than 600,000 Veterans Affairs sufferers with diabetes over three years. They in contrast individuals who obtained GLP-1 medication with these handled with medicines that decrease blood sugar. <\/p>\n

The sufferers had been divided into seven parallel trials that analyzed the chance of creating addictions to a number of substances together with alcohol, hashish, cocaine, nicotine and opioids. One other trial seemed on the threat of particular harms amongst individuals with present addictions after they took the several types of medicine.<\/p>\n

Al-Aly and his colleagues discovered that individuals beginning the GLP-1 medication had decrease dangers of creating dependancy to a number of substances. In contrast with the opposite medicines, individuals taking the GLP-1 medication had a lowered threat for dependancy: 18% for alcohol, 14% for hashish, 20% for each cocaine and nicotine, and 25% for opioids. <\/p>\n

In sufferers who already had substance use problems, beginning the GLP-1s was linked with a 31% decrease threat of emergency division visits, 26% decrease threat of hospitalizations, 25% decrease threat of suicidal ideas or makes an attempt, 39% decrease threat of overdose \u2014 and 50% decrease threat of loss of life.<\/p>\n

Total, the examine discovered that utilizing GLP-1 medication possible prevented about seven instances of substance use dysfunction and 12 incidents involving severe hurt for each 1,000 customers over three years, Al-Aly stated.<\/p>\n

Among the many examine’s limitations: It was performed inside the VA well being system, which serves a inhabitants that’s principally older, white and male, though Al-Aly stated the outcomes had been constant in additional than 35,000 ladies. It additionally contains knowledge solely from individuals with diabetes, not the overall inhabitants. <\/p>\n

The researchers additionally could not account for some elements, akin to socioeconomic standing or life-style decisions, that might have an effect on the outcomes. And the evaluation focuses on the consequences of utilizing GLP-1s in contrast with one other drug, not in contrast with no therapy.<\/p>\n

As an observational examine, the brand new evaluation confirmed that the GLP-1s are related to lowered threat of substance use problems and harms, not that the medication themselves prompted the discount.<\/p>\n

The brand new findings are hanging, stated Dr. Lorenzo Leggio, a Nationwide Institute on Drug Abuse medical director who wasn’t concerned within the examine. <\/p>\n

\u201cAlthough we do not totally perceive the mechanism, one way or the other the GLP-1 system is tackling dependancy biology and the foundational system that underlies all these problems,\u201d he stated. <\/p>\n

Diabetes and weight-loss trials have proven that the GLP-1 medication goal hormones within the intestine and the mind that management urge for food and emotions of fullness, chopping down on what’s described as \u201cmeals noise,\u201d or intrusive ideas of meals. In the identical means, this examine signifies the medication might tamp down \u201calcohol or drug noise,\u201d Leggio stated.<\/p>\n

Rising proof that GLP-1s may forestall substance use problems is thrilling, stated Dr. Anna Lembke, a Stanford College dependancy drugs specialist.<\/p>\n

\u201cWe have not actually had a brand new software in our toolbox from a pharmacotherapy perspective to deal with dependancy in a very long time,\u201d stated Lembke, noting that some dependancy specialists are already prescribing GLP-1s off-label, particularly when different remedies have failed.<\/p>\n

She cautioned that the GLP-1 medication don’t work the same way<\/a> for all customers and that they’ve dangers that should be weighed towards potential advantages. <\/p>\n

The brand new findings don’t, by themselves, justify prescribing GLP-1 medication to stop or deal with substance use problems, Al-Aly stated. That proof would wish to return from randomized managed medical trials that instantly examine using the medication towards a placebo, or dummy medicine. A number of such trials are pending, Leggio famous. <\/p>\n

The objective is discovering a brand new approach to deal with addictions, that are a number one reason behind illness and loss of life around the globe.<\/p>\n

\u201cThe consequence by way of persistent illness of those addictive medication is definitely gigantic in our society,\u201d Leggio stated.<\/p>\n

___<\/p>\n

The Related Press Well being and Science Division receives help from the Howard Hughes Medical Institute\u2019s Division of Science Schooling and the Robert Wooden Johnson Basis. The AP is solely answerable for all content material. <\/p>\n<\/div>\n